| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
|
N Engl J Med
|
2012
|
35.24
|
|
2
|
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
|
J Clin Oncol
|
2010
|
17.13
|
|
3
|
Preoperative chemoradiotherapy for esophageal or junctional cancer.
|
N Engl J Med
|
2012
|
15.43
|
|
4
|
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
|
N Engl J Med
|
1998
|
7.60
|
|
5
|
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
|
J Clin Oncol
|
2008
|
7.01
|
|
6
|
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
|
J Clin Oncol
|
2001
|
6.07
|
|
7
|
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.
|
Lancet Oncol
|
2011
|
5.94
|
|
8
|
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.
|
Lancet Oncol
|
2005
|
5.40
|
|
9
|
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.
|
Proc Natl Acad Sci U S A
|
2004
|
5.13
|
|
10
|
B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.
|
Clin Cancer Res
|
2004
|
4.65
|
|
11
|
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.
|
Clin Cancer Res
|
2005
|
4.42
|
|
12
|
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
|
J Clin Oncol
|
2009
|
4.34
|
|
13
|
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
|
Ann Surg Oncol
|
2011
|
4.22
|
|
14
|
Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.
|
J Clin Oncol
|
2003
|
2.86
|
|
15
|
PD-1: an inhibitory immunoreceptor involved in peripheral tolerance.
|
Trends Immunol
|
2001
|
2.71
|
|
16
|
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
|
JAMA Oncol
|
2015
|
2.09
|
|
17
|
Structural and functional analysis of the costimulatory receptor programmed death-1.
|
Immunity
|
2004
|
1.70
|
|
18
|
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
|
Eur J Cancer
|
2011
|
1.54
|
|
19
|
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.
|
JAMA Oncol
|
2019
|
1.39
|
|
20
|
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
|
Lancet
|
2017
|
1.38
|
|
21
|
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
|
J Clin Oncol
|
2016
|
1.24
|
|
22
|
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
|
N Engl J Med
|
2016
|
0.95
|
|
23
|
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
|
Ann Oncol
|
2016
|
0.79
|
|
24
|
Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial.
|
Eur J Cancer
|
2017
|
0.75
|
|
25
|
Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.
|
J Clin Oncol
|
2017
|
0.75
|